Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study
Authors' conclusion
This study was not able to confirm our hypothesis that increased dosing of TNF inhibitors results in improved treatment outcomes.
Study context
- Population
- Participants of the CARRA Registry who started TNFi treatment for juvenile idiopathic arthritis (JIA)
- Participants
- 328 vs 437
- Exposure
- Dose of TNFi at initiation vs treatment outcome
- Adalimumabn = 328
- Etanerceptn = 437
- Outcome
- Treatment response based on JIA ACR Pediatric criteria for improvement, clinical Juvenile Arthritis Disease Activity Score and persistence of treatment after 6 months
- Follow-up
- 3 to 7 months after start of treatment
Methodological detailspooled logistic regression, adjusted for risk factors of poor treatment response
- Pooled logistic regression
- Adjusted for risk factors of poor treatment response
Main finding
As reported in the abstract
Dose–response relationship of TNFi dose with outcome
Observational data: associations, not effects.
Original publication
Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study. Arthritis Care Res (Hoboken). Published 11 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →